Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Uveal Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital, Herlev, Herlev, Denmark
Contact: Study coordinator (Tine Juul Monberg, MD, PhD) · tine.monberg@regionh.dk · 004538683868

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Scottsdale, United States · La Jolla, United States

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

Uveal Melanoma · Melanoma · Metastatic Uveal Melanoma

Abroad (travel likely)RecruitingPHASE1

Harrison, United States · New York, United States

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Advanced Solid Tumor · Uveal Melanoma, Metastatic · Cutaneous Melanoma

Abroad (travel likely)RecruitingPHASE1

Herlev, Denmark · Barcelona, Spain

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Uveal Melanoma, Metastatic

Abroad (travel likely)RecruitingPHASE1

Sydney, Australia · Melbourne, Australia